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transaminase and cytokine levels in NAFLD 
associated with type 2 diabetes:  
a randomized clinical study
ABSTRACT
Introduction. In double-blind single center randomized 
clinical trial (RCT), the efficacy of alive probiotics sup-
plementation with smectite gel vs. placebo in type 2 
diabetes patient with non-alcoholic fatty liver disease 
(NAFLD) detected on ultrasonography (US) were 
studied. 
Material and methods. A total of 50 patients met the 
criteria for inclusion. They were randomly assigned 
to receive Symbiter Forte combination of probiotic 
biomass with smectite gel (250 mg) or placebo for 
8-weeks. The primary main outcomes were the change 
in fatty liver index (FLI) and liver stiffness (LS) meas-
ured by shear wave elastography (SWE). Secondary 
outcomes were the changes in transaminases activity, 
serum lipids and cytokines levels. 
Results. All subjects completed the study and received 
more than 90% of prescribed sachets. In respect to 
our primary endpoints, FLI and LS insignificant de-
crease in both interventional and placebo groups. 
However, when we compare mean changes across 
groups from baseline, expressed in absolute values, 
the reduction of both LS (–0.254 ± 0.85 vs. 0.262 ± 
± 0.77; p = 0.031) were observed. Analysis of sec-
ondary outcomes showed that co-administration of 
probiotic with smectite lead to significant reduction 
of alanine aminotransferase (ALT), aspartate amino-
transferase (AST), total cholesterol, IL-1b, and tumor 
necrosis factor (TNF-a) after 8 weeks. 
Conclusion. In this RCT, we confirmed previously re-
ported animal data, showing that co-administration 
of probiotic with smectite manifested with reduction 
of LS, liver transaminases and chronic systemic inflam-
mation. (Clin Diabetol 2019; 8, 4: 205–214)
Key words: diosmectite, nutraceuticals, non-alcoholic 
fatty liver disease, probiotics, Lactobacillus, 
Bifidobacterium, Propionibacterium
Introduction 
Non-alcoholic fatty liver disease (NAFLD) is an 
unique term that combines several components, in 
particular the simple steatosis with excessive intra 
hepatic fat accumulation over 5% of organ weight, 
non-alcoholic steatohepatitis (NASH), constituted by 
steatosis with development of necroinflammation, 
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fibrosis and finally cirrhosis and hepatocellular car-
cinoma [1]. NAFLD is now recognized as the hepatic 
manifestation of metabolic syndrome and often asso-
ciated with many pathologies such as type 2 diabetes 
(T2D), visceral obesity and insulin resistance (IR) [2]. 
Globally, the incidence of NAFLD is recently growing 
and has reached in Western Countries 20–30% and 
5–18% in Asia [3]. Epidemiology data supports the 
idea that NAFLD is the most common reason of chronic 
liver disease, major cause of liver-related morbidity 
and mortality and urgent problem for global public 
health [4, 5].
Currently, the treatment of NAFLD is based on life-
style changes, included enhancement of daily physical 
activity parallel with calorie restriction [2]. New thera-
peutic approaches have been under study in pre-clinical 
and clinical studies. Nowadays, modulation with gut 
microbiota composition and direct its metabolic effects 
in a perspective of prevention or treatment of NAFLD 
[6]. Among the suggested strategies, probiotic supple-
mentation, as the intake of microorganisms capable 
when administered in acceptable amounts, confers 
a health benefit on the host [7]. The positive impact of 
Lactobacilli and Bifidobacteria, the most studied and 
commonly used probiotic strains in the treatment and 
prevention of obesity-associated disorders, have been 
previously discussed in the literature [8]. Moreover, 
several potential bacterial candidates, such as Saccha-
romyces cerevisiae var. boulardii, Parabacteroides gold-
steinii, Enterobacter halii or Akkermansia muciniphila, 
have been identified and innovative mechanisms of 
action overriding their beneficial effects for obesity 
have been elucidated [9, 10]. In this regard, many re-
searchers are trying to describe the role played by the 
different bacterial strains on the NAFLD management. 
Our choice of bacteria formulation for the present 
investigation was based on previous comparative pre-
clinical studies of different probiotic strains intended 
for treatment and prevention of NAFLD and obesity [11, 
12]. Intervention with poly-probiotic mixtures contain-
ing both alive and lyophilized strains led to significant 
reduction of total and visceral adipose tissue weight, 
steatosis, and necroinflammation, and to enhanced 
insulin sensitivity in rats with monosodium-glutamate 
(MSG) induced obesity model [11–13].
Smectite is a natural silicate clay belonging to 
the dioctahedral smectite class, binds to intestinal 
mucous, forms multilayer structure with high plastic 
viscosity and powerful coating properties hence pre-
serving integrity of the mucus, and has the ability to 
absorb directly bacterial toxins, bacteria, viruses and 
bile salts [14, 15]. Diosmectite also has a protective 
effect against intestinal inflammation [16] hence 
suppressing production of cytokines such as inter-
leukin-8 from secretory epithelial cells [17] and to 
attenuating the proinflammatory action of tumor 
necrosis factor-a (TNF-a) [18]. We proposed that all 
of these pharmacological properties may be beneficial 
for the treatment of NAFLD.
Based on preclinical data, in rats with MSG-induced 
obesity supplementation of alive probiotics with 
smectite gel (Symbiter-Forte formulation) significant 
reduce chronic systemic inflammatory markers (IL-1b, 
TNF-a) [19], total NAS (NAFLD activity score) score, with 
marked decrease of lobular inflammation (0.13 ± 0.09 
vs. 0.33 ± 0.15) as compared to administration of 
probiotic alone [20]. 
Current aims were to provide single center rand-
omized clinical trial (RCT) with double-blind fashion 
to assess the efficacy of alive probiotics combination 
with smectite gel (Symbiter-Forte) vs. placebo in T2D 
patient with NAFLD detected on ultrasonography (US).
Material and methods
The recruitment started after the approval of RCT 
protocol by local commission of bioethics in Kyiv City 
Clinical Endocrinology Center. All procedures, associa-
ted with RCT, were in agreement with the guidelines of 
the 1975 Declaration of Helsinki. Before study began 
all participants gave written informed consent and 
were fully explained with purpose and its methodology.
Study design
This study was registered at ClinicalTrials.gov under 
identifier — NCT03614039 as single-center placebo 
controlled, double-blind, parallel group study with inclu-
sion of 51 T2D patients. Participants were randomized 
by the study statistician based on computer-generated 
list to intervention (Symbiter Forte) or placebo group. 
The allocation of groups was blind to investigators and 
patients. Moreover, to maintain blind and parallel study 
fashion the statistician was not aware of the allocation of 
participants to intervention. Treatment period continued 
for 8 weeks. Both placebo and intervention were admin-
istered as a sachet formulation with similar organoleptic 
characteristics (e.g., taste and appearance). The Symbiter 
Forte was supplied by Scientific and Production Company 
“O.D. Prolisok” (Ukraine). It contains combination of 
smectite gel (250 mg), supplemented with biomass of 14 
alive probiotic strains: Bifidobacterium (1 × 1010 colony 
forming units — CFU/g), Lactobacillus + Lactococcus 
(6 × 1010 CFU/g), Acetobacter (1 × 106 CFU/g) and 
short-chain fatty acids producing Propionibacterium (3 
× 1010 CFU/g) genera. Over a treatment period the par-
ticipants received 1 sachet (10 g) of probiotic-smectite 
or placebo per day. 
1.
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For minimization of the dietary changes effects, 
2 weeks before first sachet prescribed, all patients 
were instructed in one-on-one sessions with a qualified 
dietitian to follow a therapeutic lifestyle-change diet 
as classified by the National Cholesterol Education Pro-
gram (NCEP). In addition, participants were instructed 
to continue with stable anti-diabetic drugs and received 
standardized slight physical exercise for 1 hour per day.
Throughout the study, weekly phone follow-up 
visits were provided for assessment of compliance, 
adherence to the protocol, as well as the recording 
of adverse events. The effectiveness of therapy was 
compared and evaluated separately in the two groups.
Inclusion and exclusion criteria
Current study has similar design to previously 
reported by our group RCTs were effects of alive probi-
otic alone or in combination with omega-3 fatty acids 
in NAFLD were assessed [21, 22]. The main inclusion 
criteria were: adult T2D patients treated with diet and 
exercise alone or metformin, SUs and insulin at stable 
dose at least 4 weeks prior to randomization; body 
mass index (BMI) ≥ 25 kg/m2; presence of NAFLD de-
tected on US as previously described [21, 22]; aspartate 
transaminase (AST) and alanine transaminase (ALT) ≤ 3 
× upper limit of normal.
The main exclusion criteria were decompensated 
liver disease including ascites, encephalopathy or 
variceal bleeding or presence of other chronic diffuse 
liver diseases such as chronic viral hepatitis associated 
with HBV, HCV or HEV-infection; drug-induced liver 
disease; hereditary deficiency of antitrypsin-1, Wilson’s 
disease or idiopathic hemochromatosis. Patients with 
history over a two-year period or with active alcohol 
abuse which defined as consumption more than 2 
standard drinks (> 20 g/day) for women and 3 stand-
ard drinks (> 30 g/d) for men were also excluded. 
Treatment within 3 months prior to randomization 
with agents that can impact microbiota composition 
such as probiotic, prebiotic or antibiotic; vitamin E, 
omega-3 fatty acids or medications with evidence for 
effects on NAFLD (pioglitazone, glucagon-like peptide-1 
[GLP-1] analogues, dipeptidyl peptidase IV inhibitors, 
ursodeoxycholic acid) [21, 22]. Presence of uncontrolled 
cardiovascular or respiratory disease, active malignancy, 
or chronic infections.
Outcomes assessment
The primary main outcomes were the changes in 
fatty liver index (FLI) and liver stiffness (LS) measured 
by Shear Wave Elastography (SWE). The methodology 
of outcomes assessment was previously described 
[21, 22]. 
LS was measured by SWE using a multifrequency 
convex transducer (2–5 MHz) and Ultima PA ultrasound 
equipment (Radmir, Ukraine). Firstly, in B-mode we 
estimated position of liver (the ratio of the edge to 
the costal arch, the availability of acoustic windows) 
investigated both lobes of the liver and carried out their 
antero-posterior size biometrics on inspiration. Even 
or uneven contour of the liver was assessed, as well 
as acute or rounded front-bottom corner of the liver. 
We evaluated the echogenicity (normal, low or high) 
and echostructure (fine particles — 1–2 mm, medium 
particles — 3–4 mm, and coarse particles — more than 
5 mm). Sound conductivity of the liver parenchyma or 
opposite US attenuation in the front-rear direction of 
liver was evaluated by Hamaguchi’s B-mode criteria 
[21, 22].
SWE was carried out by the standard algorithm for 
2D SWE. Especially carefully navigated region of inter-
ests (ROI) and SV of 2D SWE by B-mode and removed 
SWE artifacts. We performed 10 valid measurements of 
LS in every patient, and a median value was calculated, 
the result being measured in kPa [21, 22]. 
FLI a validated prediction score for hepatic steatosis 
severity designed Bedogni et al [23]. FLI was calculated 
based on laboratory and anthropometric measures, 
including triglycerides, gamma glutamyl transferase 
(GGT), BMI, and waist circumference (WC), by using 
the following formula:
FLI = [e 0.953*loge (triglicerides) + 0.139*BMI + 0.718*loge (g-GT) + 
+ 0.053*waist circumference – 15.745)/(1 + e 0.953*loge (triglicerides) 
+ 0,139*BMI + 0.718*loge (g-GT) + 0.053*waist circumference – 15.745)] 
× 100
Secondary outcomes were the changes in transami-
nases activity, serum lipids and cytokines (TNF-a, inter-
leukin [IL]-1b, IL-6, IL-8, and interferon [IFN]-g) levels. 
All values were determined following a 12-h fasting 
period, by the hospital clinical laboratory. 
Anthropometric data including weight and height 
were measured to an accuracy of 0.1 kg and 0.5 cm, 
respectively. BMI was calculated as body weight in 
kilograms divided by the square of the participant’s 
height in meters (weight/height2). Waist circumference 
(WC, narrowest diameter between xiphoid process and 
iliac crest) was measured as well [21, 22].
Activity of ALT and AST in serum were deter-
mined by the standard biochemical methods. Serum 
concentrations of total cholesterol (TC), high-density 
lipoprotein cholesterol (HDL-C) and triglyceride (TG) 
concentrations were measured using the standard 
enzymatic methods with commercially available kits 
(BioVendor, Czech Republic). Low-density lipoprotein 
Clinical Diabetology 2019, Vol. 8, No. 4
208
cholesterol (LDL-C) concentration was calculated using 
the Friedewald equation [24].
The contents of serum interleukins (TNF-a, IL-1b, 
IL-6, IL-8, and IFN-g) were measured by enzyme-linked 
immunosorbent assay (ELISA) method. The studied 
cytokines were immobilized in 96-well plates with 
adsorption surface. They were added with primary 
and secondary enzyme-labeled antibodies (Sigma). An 
appropriate substrate was then added and produced 
a detectable product in the enzymatic reaction. The 
optical densities of the colored solutions in wells im-
mediately after the enzymatic reaction termination 
depicted the level of cytokines of the different group.
Statistical analysis
The SPSS statistical package, version 20.0 (SPSS, 
Inc., Chicago, Illinois) and GraphPad Prism, version 
6.0 (GraphPad Software, Inc., La Jolla, CA, USA) were 
used for all statistical analyses and a P value less than 
0.05 was considered statistically significant. All data in 
this study were expressed as mean ± standard devia-
tion (M ± SD) or %. Data distribution was analyzed 
using the Kolmogorov-Smirnov normality test. The 
baseline characteristics of participants in the 2 groups 
were compared using independent sample t-tests and 
chi-squared (c2) test. The changes in outcomes of the 
participants after the initiation of therapy and end of 
the trial were compared by paired sample t-tests. Analy-
sis of covariance (ANCOVA) was used to identify any 
differences between the 2 groups after intervention, 
adjusting for baseline measurements and confounders 
(BMI and sex).
Results 
In this single-center RCT, a totally 51 patients with 
NAFLD and T2D were randomly allocated to receive 
probiotic additionally supplemented with smectite 
(Symbiter Forte group, n = 26) or placebo (n = 25) for 
8 weeks, respectively. The groups were homogeneous 
according to age, sex and diagnostic criteria (Table 1). 
One patient from placebo group did not complete 
study due to lost of follow up. In final intention to 
treat analysis 50 patients were included which received 
more than 90% of prescribed sachets formulation 
in double-blind treatment. The compliance rate was 
comparable between groups — 91.7% in placebo 
and 92.3% in Symbiter Forte group respectively (p = 
0.993). Patients were satisfied with the organoleptic 
properties of both nutraceuticals formulation. Dur-
ing study period probiotic-smectite and placebo were 
well tolerated. Across the study patients complained 
only with several mostly gastrointestinal symptoms. 
Table 1. Anthropometric, clinical and laboratory parameters in examined patients (M ± SD or %)
Parameters Placebo group (n = 24) Probiotic-smectite group (n = 26) P
Age (years) 57.38 ± 9.92 53.23 ± 10.09 0.150
Duration of T2D (years) 5.33 ± 2.82 6.46 ± 5.92 0.401
Metformin, % (n) 71.4 70.0 0.905
Sulfonilureas, % (n) 53.6 43.3 0.436
Insulinotherapy, % (n) 25.0 36.7 0.337
BMI [kg/m2] 32.55 ± 3.62 33.19 ± 4.93 0.601
Weight [kg] 92.3 ± 11.49 94.81 ± 12.04 0.455
Waist circumference [cm] 94.08 ± 4.96 96.57 ± 5.01 0.084
FLI 80.16 ± 10.36 82.11 ± 10.95 0.521
LS [kPa] 7.69 ± 1.33 8.02 ± 1.39 0.401
ALT [IU/L] 35.93 ± 16.32 35.88 ± 16.89 0.991
AST [IU/L] 36.96 ± 17.66 33.31 ± 13.94 0.420
g-GT [IU/L] 45.33 ± 12.21 47.87 ± 21.84 0.088
TC [mmol/L] 5.92 ± 0.8 6.15 ± 0.83 0.320
TG [mmol/L] 2.50 ± 0,91 2,53 ± 0,99 0.888
HDL-C [mmol/L] 1.4 ± 0.27 1.33 ± 0.23 0.292
LDL-C [mmol/L] 3.41 ± 0.68 3.64 ± 0.77 0.270
TNF-a [pg/mL] 50.52 ± 18.73 51.57 ± 20.35 0.586
IL-1b [pg/mL] 47.69 ± 21.36 44.49 ± 19.88 0.850
IL-6 [pg/mL] 13.89 ± 8.80 13.22 ± 8.40 0.785
IL-8 [pg/mL] 26.05 ± 8.27 29.25 ± 8.04 0.785
g-INF 168.29 ± 75.51 187.23 ± 75.53 0.380
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All adverse events were mild, reversed spontaneously 
and did not lead to participants withdrawn from the 
study. Patients received placebo reported adverse 
events were nausea (n = 2; 8.33%), mild abdominal 
pain (n = 1; 4.16%) and short-term diarrhea (n = 2; 
8.33%). The main complaints in Symbiter Forte group 
were short-term diarrhea (n = 2; 7.69%) and con-
stipation (n = 1; 3.84%), heartburn (n = 1; 3.84%), 
mild abdominal pain (n = 1; 3.84%) and dizziness 
(n = 1; 3.84%). The total prevalence of adverse events 
was comparable between groups (placebo = 20.8% vs. 
probiotics-smectite = 23.1%, p = 0.848).
There were no significant differences between 
the groups at baseline in terms of age, sex, diabetes 
duration, anthropometric and laboratory measure-
ments (Table 1). Participants were treated with oral 
anti-diabetic agents, insulin or their combination. 
Recent study suggested that metformin, GLP-1, DPP-4 
inhibitors are known to has pleiotropic effects beyond 
glucose reduction, including improvement of lipid 
profiles, bile acids and finally gut microbiota [25, 26]. 
To elude possible interaction between incretin-mimetics 
and gut microbiota, patients treated with these class of 
anti-diabetic drugs were excluded from the study. From 
the other hand metformin nowadays recognized as first 
line therapy in patients with T2D, so it would be un-
ethical to exclude metformin from participant therapy 
regimen. In our study to avoid this bias we randomized 
equal portions of patients, treated with stable doses 
of metformin at least 4 weeks prior to study start. In 
general, at baseline proportion of patients on insulin-
therapy (p = 0.337), treated with sulfonylureas (p = 
0.436) and/or metformin (p = 0.905) were comparable 
between the groups (Table 1).
Primary outcome changes dynamics from baseline 
to 8 weeks after intervention are presented in Figures 
1 and 2. Both our primary endpoints the LS measured 
by SWE and FLI insignificant decrease after probiotic-
smectite treatment and increase in placebo groups 
(Figures 1A, B; 2A, B). However, we observed significant 
differences between mean changes of LS expressed 
in absolute value (–0.254 ± 0.85 vs. 0.262 ± 0.77; 
p = 0.031) or percentages (–4.427 ± 12.6 vs. 2.38 ± 
10.25; p = 0.043) from baseline to end of treatment in 
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Figure 1. Primary outcomes analysis with accent on LS changes. A, B — intra-group analysis of changes at baseline and after 
interventon. Data expressed in mean ± SD (A) and individual values at baseline and after 8 weeks of treatment; C, D — analysis 
of inter-group mean changes of absolute values (C) or percentages (D) from baseline to end of treatment throughout the study. 
ANCOVA was used to identify any differences between the 2 groups after intervention
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Figure 2. Primary outcomes analysis with accent on FLI changes. A, B — intra-group analysis of changes at baseline and after 
interventon. Data expreesed in mean ± SD (A) and individual values at baseline and after 8 weeks of treatment; C, D — analysis 
of inter-group mean changes of absolute values (C) or percentages (D) from baseline to end of treatment throughout the study. 
ANCOVA was used to identify any differences between the 2 groups after intervention
ANCOVA analysis (Figures 1C, D). In respect to another 
our primary endpoints, FLI mean changes across groups 
from baseline, expressed in absolute values (–0.750 
± 1.23 vs. 3.769 ± 1.84; p = 0.051) or percentages 
(–1.194 ± 8.43 vs. 4.471 ± 12.15; p = 0.06) were 
insignificant (Figures 2C, D). 
Analysis of secondary outcomes showed that 
co-administration of probiotic with smectite lead to 
significant reduction of ALT (35.88 ± 16.89 vs. 29.25 
± 10.48; p = 0.016), AST (33.31 ± 13.94 vs. 30.0 ± 
11.67; p = 0.021), TC (6.15 ± 0.83 vs. 5.86 ± 0.81; 
p = 0.010), IL-1b (44.49 ± 19.88 vs. 37.75 ± 14.02; 
p = 0.037) and TNF-a (51.57 ± 20.35 vs. 44.81 ± 18.14; 
p < 0.001) as compared to week 8 (Figures 3–5, Table 2). 
However, in between groups analysis changes remained 
significant only ALT expressed in absolute values 
(p = 0.022, Table 2). In the placebo group, changes 
were insignificant for all parameters which were in-
cluded in secondary outcomes analysis.
Discussion
In this single-center RCT, it has been demonstrated 
that probiotic additionally supplemented with smectite 
(Symbiter Forte) insignificantly decreased both FLI and 
LS values measured by SWE in primary outcomes analy-
sis. Analysis of secondary outcomes showed significant 
reduction of transaminases activity, total cholesterol, 
IL-1b and TNF-a values in intervention as compared to 
placebo group after 8 weeks of treatment. However, 
in between group ANCOVA analysis were mean values 
from baseline were analyzed, changes remained sig-
nificant only for LS and ALT activity.
Mofidi et al. [27], similar to the present study, 
used LS with transient elastography (FibroScan®) and 
hepatic steatosis (CAP score) measurement, to evalu-
ate the efficacy of synbiotic supplementation in lean 
NAFLD patients. In the randomized, double-blind, 
placebo-controlled, clinical trial hepatic steatosis and 
fibrosis reduction was observed in both groups; how-
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Figure 4. Secondary outcomes analysis with accent on lipid parameters. A, B, C, D — intra group analysis of changes at baseline 
and after interventon. Data expreesed as individual values at baseline and 8-week
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ever, the mean reduction was significantly greater in 
the synbiotic group rather than in the placebo group 
(p < 0.001) [27].
Recent RCTs with similar design [21, 22] it has 
showed that administration of alive probiotic, alone or 
in combination with omega-3 fatty acids, had signifi-
cant impact on hepatic fat content which character-
istic reduction of FLI after intervention. No significant 
changes were noted LS measured with SWE in both 
trials [21, 22]. Moreover, co-administration of alive 
multi-strain probiotic mixture with omega-3 fatty acids 
once daily for 8 weeks to patients with NAFLD charac-
terized with more pronounced changes in serum lipids 
and cytokines levels in secondary outcomes analysis as 
compared to probiotic only or probiotic-smectite, were 
we observed greatest reduction of transaminases activity.
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Figure 5. Secondary outcomes analysis with accent on cytokines changes. A, B, C, D — intra group analysis of changes at baseline 
and after interventon. Data expreesed as individual values at baseline and 8-week
Preparing RCT we have proposed that heartening 
of probiotic with smectite due to his ability support 
normal functional activity of intestinal mucosa, im-
munomodulating and cytoprotective effects, may lead 
to summation of their single positive effects. Smectite 
(bentonite) is a natural loamy poly-mineral which are 
formed by extremely small particles capable for hydra-
tion and demonstrate the most physiologically active 
properties in form of gel [28]. Smectite distributed 
on the intestinal tract surface and showed cytomuco-
protective therapeutic effect by delivering energetic 
and plastic materials to epitheliocytes, improving the 
strength of the mucosa barrier and permitting mineral 
particles to interact with glycoproteins of the mucosa 
as well as with the microbial biolayer [15, 19]. Another 
important property of smectite gel is direct absorbing 
capacity with viruses, toxins, radionuclides, heavy met-
als and bacterial endotoxins without ‘‘swallowing up” 
normal microbiota cells and physiologically important 
nutrients [17, 20]. Following the mixing of probiotic 
biomass and smectite gel, the sorbent becomes bound 
to surface structures of bacterial cells and covers them 
with a protective layer promoting the increased pro-
biotic biomass survival during its transit through the 
more aggressive gastrointestinal tract areas [19]. It is 
worth using nutraceuticals together with probiotics, as 
then possible to simultaneously improve mucosa cyto-
protection and to restore its symbiosis with intestine 
physiological microflora.
In conclusion, in this RCT we confirmed previ-
ously reported animal data, that in NAFLD patients 
co-administration to, of probiotic with smectite due 
to his absorbent activity and stabilization mucus layer 
properties can impact on synergistic enhancement of 
single effect which manifested with reduction of LS, 
liver transaminases and chronic systemic inflammation. 
The general limitations of our study were the use 
of the US technique instead of biopsy as the diagnos-
tic criteria for NAFLD, the small sample size, and the 
absence of a longer term follow up. Therefore, modu-
lation of the gut microbiota with probiotic and differ-
ent nutraceuticals represents a new branch in NAFLD 
management, but further studies in larger cohorts are 
required to determine this beneficial effect.
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Table 2. Changes in secondary outcomes parameters between baseline and week 8 (M ± SD)
Parameters Placebo group (n = 24) Probiotic-smectite group (n = 26) P
ALT [IU/L]
  Absolute value –0.37 ± 6.55 6.62 ± 13.07 0.022
  Percentage from baseline –3.79 ± 20.95 10.32 ± 32.1 0.074
AST [IU/L]
  Absolute value 0.15 ± 13.38 3.31 ± 6.88 0.293
  Percentage from baseline –7.59 ± 29.93 6.20 ± 19.22 0.056
g-GT [IU/L]
  Absolute value 1.23 ± 10.27 6.22 ± 18.8 0.256
  Percentage from baseline –0.76 ± 25.92 –1.36 ± 44.22 0.954
TC [mmol/L]
  Absolute value 0.092 ± 0.54 0.295 ± 0.53 0.195
  Percentage from baseline 1.24 ± 9.19 4.39 ± 8.55 0.214
TG [mmol/L]
  Absolute value 0.03 ± 0.79 0.355 ± 1.08 0.236
  Percentage from baseline –4.65 ± 27.35 5.408 ± 41.79 0.323
LDL-C [mmol/L]
  Absolute value 0.02 ± 0.48 0.230 ± 0.62 0.201
  Percentage from baseline –1.04 ± 15.99 4.44 ± 17.04 0.247
HDL-C [mmol/L]
  Absolute value 0.004 ± 0.21 –0.46 ± 0.28 0.435
  Percentage from baseline –1.28 ± 16.57 –6.27 ± 25.75 0.424
TNF-a [pg/mL]
  Absolute value 2.35 ± 13.78 6.75 ± 7.73 0.166
  Percentage from baseline –0.71 ± 33.65 12.17 ± 14.4 0.081
IL-1b [pg/mL]
  Absolute value 1.07 ± 8.87 6.74 ± 15.59 0.125
  Percentage from baseline –1.65 ± 22.13 6.00 ± 33.0 0.345
IL-6 [pg/mL]
  Absolute value –0.279 ± 4.93 2.28 ± 6.3 0.117
  Percentage from baseline –18.11 ± 43.72 –5.19 ± 94.2 0.542
IL-8 [pg/mL]
  Absolute value –0.78 ± 7.06 0.51 ± 5.62 0.472
  Percentage from baseline –8.24 ± 38.22 –2.44 ± 24.06 0.521
IFN-a [pg/mL]
  Absolute value 9.84 ± 32.75 21.37 ± 50.33 0.366
  Percentage from baseline 3.15 ± 21.33 4.31 ± 32.95 0.885
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